The role of tetracyclines in rosacea

American Journal of Clinical Dermatology

Volumn 11, Issue 2, 2010, Pages 79-87

  Alikhan, Ali ^a   Kurek, Laura ^a   Feldman, Steven R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTACID AGENT; AZELAIC ACID; AZITHROMYCIN; BENZOYL PEROXIDE; CARBAMAZEPINE; CLINDAMYCIN; CONTRACEPTIVE AGENT; DOXYCYCLINE; DOXYCYCLINE HYCLATE; IRON; METRONIDAZOLE; MINOCYCLINE; OXYTETRACYCLINE; PHENYTOIN; PLACEBO; PROTON PUMP INHIBITOR; RIFAMPICIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE;

ABDOMINAL DISCOMFORT; ACNE; ANTIBIOTIC RESISTANCE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN PSEUDOTUMOR; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COMPETITION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRY SKIN; DYSPEPSIA; ENDOMETRIUM POLYP; ESOPHAGUS DISEASE; ESOPHAGUS IRRITATION; ESOPHAGUS ULCER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; INFERTILITY; LIVER TOXICITY; NAUSEA; NONHUMAN; NOTE; PATIENT COMPLIANCE; PHOTOSENSITIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; ROSACEA; SERUM SICKNESS; SIDE EFFECT; SINUSITIS; SKIN BURNING SENSATION; STEVENS JOHNSON SYNDROME; STOMACH DISCOMFORT; TOOTH DISCOLORATION; UPPER RESPIRATORY TRACT INFECTION; VAGINA CANDIDIASIS; VOMITING;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DOXYCYCLINE; HUMANS; ROSACEA; TETRACYCLINE;

EID: 77949362028     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11530200-000000000-00000     Document Type: Note

References (79)

1. Conde JF, Yelverton CB, Balkrishnan R, et al. Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. J Drugs Dermatol 2007; 6 (5): 495-498
2. Marks R. The enigma of rosacea. J Dermatolog Treat 2007; 18 (6): 326-328
3. McDonnell JK, Tomecki KJ. Rosacea: an update. Cleve Clin J Med 2000; 67 (8): 587-590
4. Wilkin J,Dahl M,Detmar M,et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 2002; 46 (4): 584-587
5. Blount BW, Pelletier AL. Rosacea: a common, yet commonly overlooked, condition. Am Fam Physician 2002; 66 (3): 435-440
6. Oztas MO, Balk M, Ogus E, et al. The role of free oxygen radicals in the aetiopathogenesis of rosacea. Clin Exp Dermatol 2003; 28 (2): 188-192
7. Barco D, Alomar A. Rosacea [in Spanish]. Actas Dermosifiliogr 2008; 99 (4): 244-256
8. Feldman SR, Hollar CB, Gupta AK, et al. Women commonly seek care for rosacea: dermatologists frequently provide the care. Cutis 2001; 68 (2): 156-160
9. Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol 2004; 51 (4): 499-512; quiz 513-514
10. Bikowski JB, Goldman MP. Rosacea: where are we now? J Drugs Dermatol 2004; 3 (3): 251-261
11. Odom RB. The subtypes of rosacea: implications for treatment. Cutis 2004; 73 (1 Suppl.): 9-14
12. Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol 1998; 134 (6): 679-683
13. Frucht-Pery J, Sagi E, Hemo I, et al. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol 1993; 116 (1): 88-92
14. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol 2003; 48 (6): 836-845
15. Elewski BE, Fleischer Jr AB, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol 2003; 139 (11): 1444-1450
16. Breneman D, Savin R, VandePol C, et al. Double-blind, randomized, vehiclecontrolled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol 2004; 43 (5): 381-387
17. Baldwin HE. Tricks for improving compliance with acne therapy. Dermatol Ther 2006; 19 (4): 224-236
18. BikowskiJB. Rosacea:atiered approachtotherapy. Cutis 2000;66(4Suppl.): 3-6
19. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 2007; 56 (5): 791-802
20. Wise RD. Submicrobial doxycycline and rosacea. Compr Ther2007;33(2):78-81
21. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54 (2): 258-265
22. Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin 2007; 25 (2): 133-135
23. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100mg in the treatment of rosacea. J Drugs Dermatol 2008; 7 (6): 573-576
24. Gupta AK, Chaudhry MM. Rosacea and its management: an overview. J Eur Acad Dermatol Venereol 2005; 19 (3): 273-285
25. Thomas K, Yelverton CB, Yentzer BA, et al. The cost-effectiveness of rosacea treatments. J Dermatolog Treat 2009; 20 (2): 72-75
26. Nielsen PG. A double-blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol 1983; 109 (1): 63-65
27. Knight AG, Vickers CF. A follow-up of tetracycline-treated rosacea: with special reference to rosacea keratitis. Br J Dermatol 1975; 93 (5): 577-580
28. Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol 1966; 78 (12): 649-652
29. Marks R, Ellis J. Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet 1971; 2 (7733): 1049-1052
30. Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol 1980; 102 (4): 443-445
31. Sauer GC. Safety of long-term tetracycline therapy for acne. Arch Dermatol 1976; 112 (11): 1603-1605
32. Jackson R. How safe is low-dose long-term systemic tetracycline therapy [letter]. Can Med Assoc J 1976; 115 (9): 838
33. Witkowski JA, Parish LC. Antimicrobials in the treatment of acne and rosacea [letter]. Skinmed 2003; 2 (4): 202
34. Tan HH. Antibacterial therapy for acne: a guide to selection and use of systemic agents. Am J Clin Dermatol 2003; 4 (5): 307-314
35. Ferner RE, Moss C. Minocycline for acne [letter]. BMJ 1996; 312 (7024): 138
36. Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther 2007; 32 (5): 483-487
37. Maibach H. Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology. Cutis 1991; 48 (5): 411-417
38. Moller JK, Bak AL, Stenderup A, et al. Changing patterns of plasmidmediated drug resistance during tetracycline therapy. Antimicrob Agents Chemother 1977; 11 (3): 388-391
39. Eady EA, Jones CE, Gardner KJ, et al. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to mino-cycline. Br J Dermatol 1993; 128 (5): 556-560
40. Dickinson BD, Altman RD, Nielsen NH, et al. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 2001; 98 (5 Pt 1): 853-860
41. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65 (2): 232-260
42. Claxton AJ, Cramer J,PierceC.Asystematic reviewofthe associations between dose regimens and medication compliance. Clin Ther 2001; 23 (8): 1296-1310
43. Welling PG, Koch PA, Lau CC, et al. Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects. Antimicrob Agents Chemother 1977; 11 (3): 462-469
44. Cunha BA, Sibley CM, Ristuccia AM. Doxycycline. Ther Drug Monit 1982; 4 (2): 115-135
45. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988; 15 (6): 355-366
46. Malmborg AS. Bioavailability of doxycycline monohydrate: a comparison with equivalent doses of doxycycline hydrochloride. Chemotherapy 1984; 30 (2): 76-80
47. Bikowski JB. Treatment of rosacea with doxycycline monohydrate. Cutis 2000; 66 (2): 149-152
48. Akhyani M, Ehsani AH, Ghiasi M, et al. Comparison of efficacy of azithromycin versus doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol 2008; 47 (3): 284-288
49. Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol 1997; 36 (12): 942-946
50. Quarterman MJ, Johnson DW, Abele DC, et al. Ocular rosacea: signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol 1997; 133 (1): 49-54
51. Maatta M, Kari O, Tervahartiala T, et al. Tear fluid levels of MMP-8 are elevated in ocular rosacea: treatment effect of oral doxycycline. Graefes Arch Clin Exp Ophthalmol 2006; 244 (8): 957-962
52. Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin: involvement of protein kinase C. Arch Dermatol 1994; 130 (6): 748-752
53. Frost P, Weinstein GD, Gomez EC. Phototoxic potential of minocycline and doxycycline. Arch Dermatol 1972; 105 (5): 681-683
54. Delpre G, Kadish U, Stahl B. Induction of esophageal injuries by doxycycline and other pills: a frequent but preventable occurrence. Dig Dis Sci 1989; 34 (5): 797-800
55. Berger RS. A double-blind, multiple-dose, placebo-controlled, cross-over study to compare the incidence of gastrointestinal complaints in healthy subjects given Doryx R and Vibramycin R. J Clin Pharmacol 1988; 28 (4): 367-370
56. Oracea™ prescribing information. Newton (PA): C.P. Inc., 2006 Tan X, Huang YJ, Jiang YW, et al. Persistence of oxytetracycline residues in milk after the intrauterine treatment of lactating cows for endometritis. Vet Rec 2007; 161 (17): 585-586
57. Perlmutter A, Abramovits W, Gupta AK. Oracea (doxycycline monohydrate). Skinmed 2006; 5 (5): 238-240
58. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003; 139 (4): 459-464
59. Walker C, Bradshaw M. The effect of oral doxycycline 100 mg once-daily for 14 days on the nasopharyngeal flora of healthy volunteers: a preliminary analysis [poster]. 26th Anniversary Fall Clinical Dermatology Conference; 2007 Oct 18-27: Las Vegas (NV)
60. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998; 12 (2): 12-26
61. Kurokawa I, Nishijima S, Kawabata S. Antimicrobial susceptibility of Propionibacterium acnes isolated from acne vulgaris. Eur J Dermatol 1999; 9 (1): 25-28
62. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51 (3): 327-41; quiz 342-344
63. Wilkin JK. Effect of subdepressor clonidine on flushing reactions in rosacea: change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol 1983; 119 (3): 211-214
64. Dahl MV. Pathogenesis of rosacea. Adv Dermatol 2001; 17: 29-45
65. Berman B, Perez OA, Zell D. Update on rosacea and anti-inflammatory-dose doxycycline. Drugs Today (Barc) 2007; 43 (1): 27-34
66. Theobald K, Bradshaw M, Leyden J. Anti-inflammatory dose doxycycline (40 mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea. Skinmed 2007; 6 (5): 221-226
67. Fowler Jr JF. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol 2007; 6 (6): 641-645
68. Sanchez J, Somolinos AL, Almodovar PI, et al. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol 2005; 53 (5): 791-797
69. Thomas J, Walker C, Bradshaw M. Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility. J Periodontol 2000; 71 (9): 1472-1483
70. Walker C, Preshaw PM, Novak J, et al. Long-term treatment with sub-antimicrobial dose doxycycline has no antibacterial effect on intestinal flora. J Clin Periodontol 2005; 32 (11): 1163-1169
71. Low-dose doxycycline (Oracea) for rosacea. Med Lett Drugs Ther 2007; 49 (1252): 5-6
72. TaCN, ShineWE, McCulley JP,etal. Effectsofminocyclineonthe ocular floraof patients with acne rosacea or seborrheic blepharitis. Cornea 2003; 22 (6): 545-548
73. Fleischer Jr AB, Dinehart S, Stough D, et al. Safety and efficacy of a new extended-release formulation of minocycline. Cutis 2006; 78 (4 Suppl.): 21-31
74. Espagne E, Guillaume JC, Archimbaud A, et al. Double-blind study versus excipient of 0.75% metronidazole gel in the treatment of rosacea. Ann Der-matol Venereol 1993; 120 (2): 129-133
75. Conde JF, Kaur M, Fleischer Jr AB, et al. Adherence to clocortolone pivalate cream 0.1% in a pediatric population with atopic dermatitis. Cutis 2008; 81 (5): 435-441
76. Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007; 56 (2): 211-216
77. Carroll CL, Feldman SR, Camacho FT, et al. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol 2004; 51 (2): 212-216
78. Balkrishnan R, Carroll CL, Camacho FT, et al. Electronic monitoring of medication adherence in skin disease: results of a pilot study. J Am Acad Dermatol 2003; 49 (4): 651-654
79. Tusa MG, Ladd M, Kaur M, et al. Adapting electronic adherence monitors to standard packages of topical medications. J Am Acad Dermatol 2006; 55 (5): 886-887